Open an account

Reviva Pharmaceuticals Holdings

RVPH · NASDAQ

$0.46+$0.01 (+2.22%)TodayMarket closed ·
Prev close $0.45

About RVPH

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 14 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, inflammatory, and cardiometabolic diseases. Its pipeline includes two drug candidates, brilaroxazine (RP5063) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Employees
14
Headquarters
Cupertino, California
Listed
Oct 18, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
revivapharma.com

RVPH key statistics

Market cap
6.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
28.32K
Volume
32.42K
Open price
$0.4425
High today
$0.50
Low today
$0.385
52 Week high
$0.78
52 Week low
$0.3082

Reviva Pharmaceuticals Holdings (RVPH) at a glance

As of Oct 20, 2026, Reviva Pharmaceuticals Holdings (RVPH) shares are priced at $0.46, giving the company a market cap of 6.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.385 and $0.50. The current price is 19.5% above the day's low and 8.0% below its high.

Volume so far is 32.42K shares, in line with the average of 28.32K shares a day.

Over the past year Reviva Pharmaceuticals Holdings has ranged from $0.3082 to $0.78, and now sits 32% of the way up that range.

Reviva Pharmaceuticals Holdings met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q1 FY26 it reported -$0.46 per share against an estimate of -$0.6344.

The average analyst price target is $38.15, 8193.0% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 6 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 7 analystsAvg $38.15
Low
$7.07
Now
$0.46
High
$84.00

RVPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 25.2% on average.

  1. Q1 FY24: reported -$5.00 per share against an estimate of -$7.68
  2. Q2 FY24: reported -$5.20 per share against an estimate of -$5.92
  3. Q3 FY24: reported -$5.00 per share against an estimate of -$5.02
  4. Q4 FY24: reported -$3.00 per share against an estimate of -$4.39
  5. Q1 FY25: reported -$2.60 per share against an estimate of -$3.72
  6. Q2 FY25: reported -$2.40 per share against an estimate of -$2.24
  7. Q3 FY25: reported -$1.20 per share against an estimate of -$1.98
  8. Q1 FY26: reported -$0.46 per share against an estimate of -$0.6344

RVPH news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Dow Falls 200 Points; US Producer Prices Surge In April

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Sweta Killa

    Robert F. Kennedy Jr. Wants To Take 'Clear And Decisive Action' On Psychiatric Drugs Amid 'Deprescribing' Push: Big Pharma Should Pay Attention

  • Caroline Ryan

    Deal Dispatch: Amazon Buys Globalstar, Instacart Grabs Instaleap, QVC Announces Bankruptcy

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Gold Tumbles Over 6%; Accenture Earnings Top Views

  • Avi Kapoor

    Dow Falls Over 300 Points; US Initial Jobless Claims Fall

Similar companies

Companies in the same industry as Reviva Pharmaceuticals Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.